Thus, the antibody inhibits the activation of HGF/MET axis downstream signaling and tumor growth, and reduces the release of the inflammatory factor IL-6, thus suggesting a vast therapeutic potential (Sun et al., 2017). Here, MET is linked to neoplasm.